Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Wallac OY currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, which distributes the prosecution risk across different individuals. The portfolio is localized within 1 distinct art unit, implying that the company's biotechnology filings are being evaluated under a consistent set of departmental standards. This combination of multiple examiners within a single unit provides a variety of perspectives while maintaining a stable technical context for the applications. Such a strategy can be useful for identifying the most effective arguments within a specific biotechnology field.
The busiest examiner for the portfolio is OGUNTADE, ELIZABETH BISOLA, who is overseeing 1 pending office action. This count of 1 pending action for the busiest examiner, out of a total of 2 pending actions, shows how the workload is divided among the 2 distinct examiners. Practitioners can expect to interact with different examiners while navigating the single art unit where the company's active matters reside. This distribution ensures that the company's progress in the biotechnology sector is not entirely dependent on the findings of a single examiner. By managing these pending office actions simultaneously, the company can gain a broader understanding of the examination landscape for its pharmaceutical products.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNTADE, ELIZABETH BISOLA | 1 | 0.0% | +0.0% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773273 | METHODS OF ANALYZING A BIOLOGICAL SAMPLE | SITTON, JEHANNE SOUAYA | 4d overdue |
| 18647364 | NEWBORN SCREENING FOR CONGENITAL HEART DEFECT USING CARDIOVASCULAR BIOMARKERS IN DRIED BLOOD SAMPLES | OGUNTADE, ELIZABETH BISOLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773273 | METHODS OF ANALYZING A BIOLOGICAL SAMPLE | SITTON, JEHANNE SOUAYA | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647364 | NEWBORN SCREENING FOR CONGENITAL HEART DEFECT USING CARDIOVASCULAR BIOMARKERS IN DRIED BLOOD SAMPLES | OGUNTADE, ELIZABETH BISOLA | — | §101§102§103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 17773273 | METHODS OF ANALYZING A BIOLOGICAL SAMPLE | SITTON, JEHANNE SOUAYA | 1682 | §103§112 | Non-Final OA | 4d overdue | Pending | Apr 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial